Muramyl tripeptide in chemotherapy improves overall osteosarcoma survival
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology GroupJ Clin Oncol. 2008 Feb 1;26(4):633-8. doi: 10.1200/JCO.2008.14.0095
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Dr. Paul A. Meyers discusses the addition of muramyl tripeptide to chemotherapy in the treatment of Osteosarcoma.
662 osteosarcoma patients without detectable metastatic disease were either randomized to three drug (cisplatin, doxorubicin, methotrexate) or four drug chemotherapy (cisplatin, doxorubicin, methotrexate, and ifosfamide). A further comparison was conducted on the effects of the addition muramyl tri-peptide (MTP) to both chemotherapy regimens. Four- and six-year evaluations of event free survival (...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE